Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene (ALK) are likely to fare better if treated with the targeted therapy (crizotinib) than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.